Fairvalue-Calculator Fairvalue-Calculator

Beijing Foyou Pharma CO.,LTD (601089) Fair Value & Analysis

Healthcare · CN · Market cap 8.0B CNY

Price¥16.30
Fair Value¥17.52
Upside+7.5%
Quality95/100
Evidence: High Range ¥12.26 – ¥22.78

Analysis

Beijing Foyou Pharma CO.,LTD (601089) currently trades at ¥16.30, while our model-based Fair Value estimate is ¥17.52 — implying the stock looks roughly 7.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Beijing Foyou Pharma CO.,LTD engages in the research and development, production, and sale of pharmaceutical formulation and medical devices China. The company offers chemical drugs; traditional Chinese medicine; raw materials; and medical devices, such as negative pressure drainage device, digital urine collection bags, dynamic urine output monitor, disposable pressure sensor, urodynamic monitoring device, nasal air filter, medical micro-mesh nebulizer, disposable atomizer, disposable oxygen mask, and disposable oxygen tubing. It sells its products through medical institutions and retail outlets. The company's products cover cardiovascular system, chronic kidney disease, dermatology, digestive system, diabetes, neuropsychiatric system, and gynecology areas. Beijing Foyou Pharma CO.,LTD was incorporated in 1999 and is headquartered in Beijing, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.